Komori
Eisai (4523) · InitiativeFirst statedLatest Revision of earnings forecasts (2026-05-15): "Advanced"

Development of E6742 for systemic lupus erythematosus

First written in FY2022. 1 of 2 entries say "Advanced", first in 2026-05-15. Latest entry: 2026-05-15.

2entries
5years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20222022: 120222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Clinical Development of E6742 for Systemic Lupus ErythematosusA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. 2026-05-15AdvancedRevision of earnings forecasts

    「「E6742」について、日本において、全身性エリテマトーデを対象としたフェーズⅡ試験を開始しました。」

    E6742の全身性エリテマトーデ向け開発がフェーズⅡ試験開始段階へ進んだ。
  2. FY2022First statedAnnual report

    「Toll様受容体7/8阻害剤「E6742」について、全身性エリテマトーデスを対象としたフェーズⅠ/Ⅱ試験を、日本において開始しました。」

    E6742について、全身性エリテマトーデスを対象とする日本でのフェーズⅠ/Ⅱ試験開始が初めて記載された。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet. It last moved in the Revision of earnings forecasts of 2026-05-15: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.